This article is more than 5 years old. Information may no longer be current.

Myeloma expert joins Tisch Cancer Institute at Mount Sinai

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bart Barlogie, MD, has joined the faculty at The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai.

Barlogie will serve as director of research in the myeloma program, which is led by Sundar Jagannath, MD.

“We are extremely excited for Dr. Barlogie to join us as he brings a wealth of expertise and innovation in myeloma research,” Steven Burakoff, MD, Lillian and Henry M. Stratton professor of cancer medicine and director of The Tisch Cancer Institute at Mount Sinai, said in a press release. “With him and Dr. Jagannath at the helm, Mount Sinai will have the country’s premier myeloma program.”

Barlogie spent 20 years as director of Myeloma Institute for Research & Therapy at University of Arkansas for Medical Sciences. His work has focused on biological and therapeutic research, including chemotherapy, immunotherapy and hematopoietic stem cell transplantation.

“I am thrilled to join Mount Sinai and collaborate once again with my good friend and colleague, Dr. Sundar Jagannath,” Barlogie said in the press release. “I am excited to collaborate with Sundar and other elite scientists to find novel approaches for patients with high-risk myeloma. We have a unique opportunity to move the field forward, and our understanding of the underlying mechanisms in the transition to malignant disease.”